Bristol Cash per Share

BMYMP
 Stock
  

USD 1,200  10.00  0.84%   

Bristol Myer Squi fundamentals help investors to digest information that contributes to Bristol Myer's financial success or failures. It also enables traders to predict the movement of Bristol OTC Stock. The fundamental analysis module provides a way to measure Bristol Myer's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Bristol Myer otc stock.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.
  

Bristol Cash per Share Analysis

Bristol Myer's Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Cash per Share 
 = 
Total Cash 
Average Shares 
More About Cash per Share | All Equity Analysis

Current Bristol Myer Cash per Share

    
  3.72 X  
Most of Bristol Myer's fundamental indicators, such as Cash per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bristol Myer Squi is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
Compare to competition

In accordance with the recently published financial statements, Bristol Myer Squi has a Cash per Share of 3.72 times. This is 14.48% lower than that of the Healthcare sector and 77.64% lower than that of the Drug Manufacturers - Major industry. The cash per share for all United States stocks is 25.75% higher than that of the company.

Bristol Cash per Share Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bristol Myer's direct or indirect competition against its Cash per Share to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Bristol Myer could also be used in its relative valuation, which is a method of valuing Bristol Myer by comparing valuation metrics of similar companies.
Bristol Myer is currently under evaluation in cash per share category among related companies.

Bristol Fundamentals

About Bristol Myer Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Bristol Myer Squi's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bristol Myer using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bristol Myer Squi based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York. Bristol Myers operates under Drug Manufacturers - Major classification in USA and is traded on OTC Market. It employs 23700 people.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Bristol Myer in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Bristol Myer's short interest history, or implied volatility extrapolated from Bristol Myer options trading.

Pair Trading with Bristol Myer

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bristol Myer position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bristol Myer will appreciate offsetting losses from the drop in the long position's value.

Moving against Bristol Myer

-0.84AAPLApple Inc Fiscal Year End 27th of October 2022 PairCorr
-0.79LOWLowes Companies TrendingPairCorr
-0.75CVSCVS Corp TrendingPairCorr
-0.66SBUXStarbucks Corp Fiscal Year End 27th of October 2022 PairCorr
The ability to find closely correlated positions to Bristol Myer could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bristol Myer when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bristol Myer - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bristol Myer Squi to buy it.
The correlation of Bristol Myer is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bristol Myer moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bristol Myer Squi moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bristol Myer can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Continue to Bristol Myer Piotroski F Score and Bristol Myer Altman Z Score analysis. You can also try Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.

Complementary Tools for analysis

When running Bristol Myer Squi price analysis, check to measure Bristol Myer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bristol Myer is operating at the current time. Most of Bristol Myer's value examination focuses on studying past and present price action to predict the probability of Bristol Myer's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Bristol Myer's price. Additionally, you may evaluate how the addition of Bristol Myer to your portfolios can decrease your overall portfolio volatility.
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Go
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Is Bristol Myer's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bristol Myer. If investors know Bristol will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bristol Myer listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Bristol Myer Squi is measured differently than its book value, which is the value of Bristol that is recorded on the company's balance sheet. Investors also form their own opinion of Bristol Myer's value that differs from its market value or its book value, called intrinsic value, which is Bristol Myer's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bristol Myer's market value can be influenced by many factors that don't directly affect Bristol Myer's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bristol Myer's value and its price as these two are different measures arrived at by different means. Investors typically determine Bristol Myer value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bristol Myer's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.